2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Hellmich, Bernhard; Agueda, Ana; Monti, Sara; Buttgereit, Frank; de Boysson, Hubert; Brouwer, Elisabeth; Cassie, Rebecca; Cid, Maria C; Dasgupta, Bhaskar; Dejaco, Christian; Hatemi, Gulen; Hollinger, Nicole; Mahr, Alfred; Mollan, Susan P; Mukhtyar, Chetan; Ponte, Cristina; Salvarani, Carlo; Sivakumar, Rajappa; Tian, Xinping; Tomasson, Gunnar; ... (2020). 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the rheumatic diseases, 79(1), pp. 19-30. BMJ Publishing Group 10.1136/annrheumdis-2019-215672

Text 2018_Update_of_the_EULAR.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (620kB)

BACKGROUND

Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations.

METHODS

Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations.

RESULTS

Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons.

CONCLUSIONS

We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.

Interest & Impact

Downloads

1 since deposited on 23 Dec 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item